Thioredoxins in cardiovascular disease

Canadian Journal of Physiology and Pharmacology

Volumn 93, Issue 11, 2015, Pages 903-911

  Whayne, Thomas F ^a   Parinandi, Narasimham ^b   Maulik, Nilanjana ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Inflammation; Oxidative stress; Reactive oxygen species; Thioredoxin; Thioredoxin reductase

Indexed keywords

ANGIOTENSIN II; ANTIOXIDANT; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; THIOREDOXIN REDUCTASE; TXN PROTEIN, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BIOCHEMISTRY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDITIS; CELL CYCLE ARREST; CELL DEATH; CONFORMATIONAL TRANSITION; CONGESTIVE HEART FAILURE; EMBRYO DEVELOPMENT; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERLIPEMIA; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; MYOCARDITIS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BLOCKING; REVIEW; TUMOR GROWTH; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; REACTIVE OXYGEN SPECIES; THIOREDOXINS;

EID: 84945361988     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2015-0105     Document Type: Review

References (53)

1. Adluri, R.S., Thirunavukkarasu, M., Zhan, L., Akita, Y., Samuel, S.M., Otani, H., et al. 2011. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. J. Mol. Cell. Cardiol. 50(1): 239-247. doi:10.1016/j.yjmcc.2010.11.002. PMID:21074540.
2. Aggarwal, N.T., and Makielski, J.C. 2013. Redox control of cardiac excitability. Antioxid. Redox Signal. 18(4): 432-468. doi:10.1089/ars.2011.4234. PMID: 22897788.
3. Bodnar, J.S., Chatterjee, A., Castellani, L.W., Ross, D.A., Ohmen, J., Cavalcoli, J., et al. 2002. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat. Genet. 30(1): 110-116. doi:10.1038/ng811. PMID:11753387.
4. Buettner, G.R. 1993. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300(2): 535-543. doi:10.1006/abbi.1993.1074. PMID:8434935.
5. Cai, L. 2006. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic. Biol. Med. 41(6): 851-861. doi:10.1016/j.freeradbiomed.2006.06.007. PMID:16934665.
6. Cohen, M.V., and Downey, J.M. 2015. Signalling pathways and mechanisms of protection in pre-and postconditioning: historical perspective and lessons for the future. Br. J. Pharmacol. 172(8): 1913-1932. doi:10.1111/bph.12903. PMID:25205071.
7. Cook, K.M., and Figg, W.D. 2010. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 60(4): 222-243. doi:10.3322/caac.20075. PMID:20554717.
8. Dai, S., He, Y., Zhang, H., Yu, L., Wan, T., Xu, Z., et al. 2009. Endothelial-specific expression of mitochondrial thioredoxin promotes ischemia-mediated arteriogenesis and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 29(4): 495-502. doi:10.1161/ATVBAHA.108.180349. PMID:19150880.
9. Deng, Z.H., Cao, H.Q., Hu, Y.B., Wen, J.F., and Zhou, J.H. 2011. TRX is up-regulated by fibroblast growth factor-2 in lung carcinoma. APMIS, 119(1): 57-65. doi:10.1111/j.1600-0463.2010.02692.x. PMID:21143527.
10. Govender, J., Loos, B., Marais, E., and Engelbrecht, A.M. 2014. Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin. J. Pineal Res. 57(4): 367-380. doi:10.1111/jpi.12176. PMID:25230823.
11. Hamada, Y., Miyata, S., Nii-Kono, T., Kitazawa, R., Kitazawa, S., Higo, S., et al. 2007. Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. Nephrol. Dial. Transplant. 22(6): 1547-1557. doi:10.1093/ndt/gfm099. PMID:17360766.
12. Hirai, N., Kawano, H., Yasue, H., Shimomura, H., Miyamoto, S., Soejima, H., et al. 2003. Attenuation of nitrate tolerance and oxidative stress by an angiotensin II receptor blocker in patients with coronary spastic angina. Circulation, 108(12): 1446-1450. doi:10.1161/01.CIR.0000089092.61590.A8. PMID:12952843.
13. Holmgren, A. 1979. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J. Biol. Chem. 254(19): 9627-9632. PMID:385588.
14. Holmgren, A. 1985. Thioredoxin. Annu. Rev. Biochem. 54: 237-271. doi:10.1146/annurev.bi.54.070185.001321. PMID:3896121.
15. Holmgren, A. 1989. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264(24): 13963-13966. PMID:2668278.
16. Hoshino, T., Nakamura, H., Okamoto, M., Kato, S., Araya, S., Nomiyama, K., et al. 2003. Redox-active protein thioredoxin prevents proinflammatory cytokineor bleomycin-induced lung injury. Am. J. Respir. Crit. Care Med. 168(9): 1075-1083. doi:10.1164/rccm.200209-982OC. PMID:12816738.
17. Ichiki, H., Hoshino, T., Kinoshita, T., Imaoka, H., Kato, S., Inoue, H., et al. 2005. Thioredoxin suppresses airway hyperresponsiveness and airway inflammation in asthma. Biochem. Biophys. Res. Commun. 334(4): 1141-1148. doi:10.1016/j.bbrc.2005.07.007. PMID:16039995.
18. Jakupoglu, C., Przemeck, G.K., Schneider, M., Moreno, S.G., Mayr, N., Hatzopoulos, A.K., et al. 2005. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol. Cell. Biol. 25(5): 1980-1988. doi:10.1128/MCB.25.5.1980-1988.2005. PMID:15713651.
19. Jones, D.P. 2008. Radical-free biology of oxidative stress. Am. J. Physiol. Cell Physiol. 295(4): C849-C868. doi:10.1152/ajpcell.00283.2008. PMID:18684987.
20. Kakisaka, Y., Nakashima, T., Sumida, Y., Yoh, T., Nakamura, H., Yodoi, J., and Senmaru, H. 2002. Elevation of serum thioredoxin levels in patients with type 2 diabetes. Horm. Metab. Res. 34(3): 160-164. doi:10.1055/s-2002-23201. PMID:11972307.
21. Kawano, H., Yasue, H., Hirai, N., Yoshida, T., Fukushima, H., Miyamoto, S., et al. 2003. Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state. Int. J. Clin. Pharmacol. Ther. 41(8): 346-353. doi:10.5414/CPP41346. PMID:12940591.
22. Kim, W.J., Cho, H., Lee, S.W., Kim, Y.J., and Kim, K.W. 2005. Antisensethioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation. Int. J. Oncol. 26(4): 1049-1052. PMID:15754001.
23. Kinoshita, T., Hoshino, T., Imaoka, H., Ichiki, H., Okamoto, M., Kawayama, T., et al. 2007. Thioredoxin prevents the development and progression of elastase-induced emphysema. Biochem. Biophys. Res. Commun. 354(3): 712-719. doi:10.1016/j.bbrc.2007.01.053. PMID:17257583.
24. Kobayashi, N., Yamada, Y., Ito, W., Ueki, S., Kayaba, H., Nakamura, H., et al. 2009. Thioredoxin reduces C-C chemokine-induced chemotaxis of human eosinophils. Allergy, 64(8): 1130-1135. doi:10.1111/j.1398-9995.2009.01969.x. PMID: 19208085.
25. Kuhara, T., Watanabe, D., Akita, Y., Takeo, T., Ishida, N., Nakano, A., et al. 2008. Thioredoxin upregulation by 5-aminolaevulinic acid-based photodynamic therapy in human skin squamous cell carcinoma cell line. Photodermatol. Photoimmunol. Photomed. 24(3): 142-146. doi:10.1111/j.1600-0781.2008.00354.x. PMID:18477133.
26. Kuljaca, S., Liu, T., Dwarte, T., Kavallaris, M., Haber, M., Norris, M.D., et al. 2009. The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. Carcinogenesis, 30(11): 1865-1871. doi:10.1093/carcin/bgp225. PMID: 19773351.
27. Kurimoto, C., Kawano, S., Tsuji, G., Hatachi, S., Jikimoto, T., Sugiyama, D., et al. 2007. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjogren’s syndrome. J. Rheumatol. 34(10): 2035-2043. PMID:17896802.
28. Li, L.F., Liao, S.K., Lee, C.H., Tsai, Y.H., Huang, C.C., and Quinn, D.A. 2005. Ventilation-induced neutrophil infiltration and apoptosis depend on apoptosis signal-regulated kinase 1 pathway. Crit. Care Med. 33(9): 1913-1921. doi:10.1097/01.CCM.0000178179.48050.BC. PMID:16148459.
29. Luthman, M., and Holmgren, A. 1982. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry, 21(26): 6628-6633. doi:10.1021/bi00269a003. PMID:7159551.
30. Matsushima, S., Zablocki, D., and Sadoshima, J. 2011. Application of recombinant thioredoxin1 for treatment of heart disease. J. Mol. Cell. Cardiol. 51(4): 570-573. doi:10.1016/j.yjmcc.2010.09.020. PMID:20955713.
31. Milovanova, T.N., Bhopale, V.M., Sorokina, E.M., Moore, J.S., Hunt, T.K., Hauer-Jensen, M., et al. 2009. Hyperbaric oxygen stimulates vasculogenic stem cell growth and differentiation in vivo. J. Appl. Physiol. (1985), 106(2): 711-728. doi:10.1152/japplphysiol.91054.2008. PMID:19023021.
32. Miranda, H.R., Castro, G.P., Verdejo, P.H., Chiong, M., Diaz-Araya, G., Mellado, R., et al. 2007. [Oxidative stress and inflammation in heart failure: mechanisms of damage and therapeutic alternatives]. Rev. Med. Chil. 135(8): 1056-1063. [Article in Spanish] doi:10.4067/S0034-98872007000800015. PMID:17989865.
33. Miranda-Vizuete, A., Ljung, J., Damdimopoulos, A.E., Gustafsson, J.A., Oko, R., Pelto-Huikko, M., and Spyrou, G. 2001. Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa. J. Biol. Chem. 276(34): 31567-31574. doi:10.1074/jbc.M101760200. PMID: 11399755.
34. Miyamoto, S., Kawano, H., Takazoe, K., Soejima, H., Sakamoto, T., Hokamaki, J., et al. 2004. Vitamin E improves fibrinolytic activity in patients with coronary spastic angina. Thromb. Res. 113(6): 345-351. doi:10.1016/j.thromres.2004.03.016. PMID:15226088.
35. Nordberg, J., and Arner, E.S. 2001. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31(11): 1287-1312. doi: 10.1016/S0891-5849(01)00724-9. PMID:11728801.
36. Pajukanta, P., Lilja, H.E., Sinsheimer, J.S., Cantor, R.M., Lusis, A.J., Gentile, M., et al. 2004. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat. Genet. 36(4): 371-376. doi:10.1038/ng1320. PMID:14991056.
37. Roul, D., and Recchia, F.A. 2015. Metabolic Alterations Induce oxidative stress in diabetic and failing hearts: different pathways, same outcome. Antioxid. Redox Signal. In press. doi:10.1089/ars.2015.6311. PMID:25836025.
38. Saccoccia, F., Angelucci, F., Boumis, G., Carotti, D., Desiato, G., Miele, A.E., and Bellelli, A. 2014. Thioredoxin reductase and its inhibitors. Curr. Protein Pept. Sci. 15(6): 621-646. doi:10.2174/1389203715666140530091910. PMID:24875642.
39. Sakuma, K., Nakamura, H., Nakamura, T., Hoshino, Y., Ueda, S., Ichikawa, M., et al. 2007. Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease. Intern. Med. 46(23): 1905-1909. doi:10.2169/internal medicine.46.0220. PMID:18057762.
40. Samuel, S.M., Thirunavukkarasu, M., Penumathsa, S.V., Koneru, S., Zhan, L., Maulik, G., et al. 2010. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation, 121(10): 1244-1255. doi:10.1161/CIRCULATIONAHA.109.872481. PMID:20194885.
41. Schulz, E., Wenzel, P., Munzel, T., and Daiber, A. 2014. Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid. Redox Signal. 20(2): 308-324. doi:10.1089/ars.2012.4609. PMID:22657349.
42. Selvaraju, V., Joshi, M., Suresh, S., Sanchez, J.A., Maulik, N., and Maulik, G. 2012. Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease: an overview. Toxicol. Mech. Methods, 22(5): 330-335. doi:10.3109/ 15376516.2012.666648. PMID:22394340.
43. Shioji, K., Matsuura, Y., Iwase, T., Kitaguchi, S., Nakamura, H., Yodoi, J., et al. 2002. Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thioredoxin: a case report. Circ. J. 66(10): 977-980. doi:10.1253/circj.66.977. PMID:12381097.
44. Shono, M., Yoshimura, M., Nakayama, M., Yamamuro, M., Abe, K., Suzuki, S., et al. 2007. Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ. J. 71(7): 1040-1046. doi:10.1253/circj.71.1040. PMID:17587708.
45. Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R., and Gersl, V. 2009. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 61(1): 154-171. doi:10.1016/S1734-1140(09)70018-0. PMID:19307704.
46. Taniguchi, Y., Taniguchi-Ueda, Y., Mori, K., and Yodoi, J. 1996. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic Acids Res. 24(14): 2746-2752. doi:10.1093/nar/24.14.2746. PMID:8759006.
47. Thannickal, V.J., and Fanburg, B.L. 2000. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 279(6): L1005-L1028. PMID: 11076791.
48. Thomas, E.L., Lehrer, R.I., and Rest, R.F. 1988. Human neutrophil antimicrobial activity. Rev. Infect. Dis. 10(Suppl. 2): S450-S456. doi:10.1093/cid/10.Supplement_2.S450. PMID:3055215.
49. Tsuji, G., Koshiba, M., Nakamura, H., Kosaka, H., Hatachi, S., Kurimoto, C., et al. 2006. Thioredoxin protects against joint destruction in a murine arthritis model. Free Radic. Biol. Med. 40(10): 1721-1731. doi:10.1016/j.freeradbiomed.2006.01.006. PMID:16678011.
50. Tsujita, K., Shimomura, H., Kaikita, K., Kawano, H., Hokamaki, J., Nagayoshi, Y., et al. 2006. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ. J. 70(7): 832-837. doi:10.1253/circj.70.832. PMID:16799234.
51. Violi, F., Pastori, D., Pignatelli, P., and Loffredo, L. 2014. Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. Europace, 16(8): 1107-1116. doi:10.1093/europace/euu040. PMID:24706090.
52. Welsh, S.J., Bellamy, W.T., Briehl, M.M., and Powis, G. 2002. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 62(17): 5089-5095. PMID:12208766.
53. Zeng, C., Villar, V.A., Yu, P., Zhou, L., and Jose, P.A. 2009. Reactive oxygen species and dopamine receptor function in essential hypertension. Clin. Exp. Hypertens. 31(2): 156-178. doi:10.1080/10641960802621283. PMID:19330604.